Celgene International Sárl (CELG) Release: Phase II Study of ISTODAX® in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL): A Sub-Analysis of Patients with Most Common Subtypes of PTCL Presented at American Society of Hematology  
12/13/2011 6:49:00 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (Nasdaq:CELG) announced data from a sub-analysis of a Phase II, multicenter, international, open-label study of ISTODAX (romidepsin) in refractory or relapsed PTCL following prior systemic therapy were presented by Professor Bertrand Coiffier, Hospices Civils de Lyon and Université Lyon1, Lyon, France at the 53rd American Society of Hematology Annual Meeting.